TORONTO, Sept. 09, 2021 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that it has selected Treatment-Resistant Depression…

Source

Previous articleField Trip Health Ltd. to Pursue Treatment Resistant Depression and Postpartum Depression as Indications for FT-104
Next articleWesana Health Announces Closing of PsyTech Acquisition